Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Eflapegrastim→

Eflapegrastim Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1384099-30-2
Molecular formula
C3070H4764N806O927S23.(C2H4O)n
Molecular weight
72100 g/mol
Drug class
Long-acting pegylated granulocyte colony-stimulating factor (G-CSF) analog
Mechanism of action
Binds G-CSF receptors on haematopoietic progenitor cells and neutrophils, stimulating proliferation, differentiation and survival of neutrophil precursors and increasing circulating neutrophil counts.
Indications / reported uses
  • To decrease the incidence of infection, manifested as febrile neutropenia, in adults with non-myeloid malignancies receiving myelosuppressive chemotherapy associated with a clinically significant incidence of febrile neutropenia; not indicated for stem-cell mobilisation

Sources: US DailyMed — Rolvedon (eflapegrastim-xnst) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Eflapegrastim Environmental Risk Assessment (ERA) (the Eflapegrastim ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.